"Polymorphisms in Folate Metabolism Genes As Maternal Risk Factor for Neural Tube Defects: an Updated Meta-analysis"

Overview

Journal Metab Brain Dis

Publisher Springer

Specialties Endocrinology
Neurology

Date 2014 Jul 10

PMID 25005003

Citations 27

Authors

Upendra Yadav

Pradeep Kumar

Sushil Kumar Yadav

Om Prakash Mishra

Vandana Rai

Affiliations

Soon will be listed here.

Abstract

Epidemiological studies have evaluated the association between maternal methylenetetrahydrofolate reductase (MTHFR) C677T, A1298C and methionine synthase reductase (MTRR) A66G polymorphisms and risk of neural tube defects (NTDs) in offspring. However, the results from the published studies on the association between these three polymorphisms and NTD risk are conflicting. To derive a clearer picture of association between these three maternal polymorphisms and risk of NTD, we performed meta-analysis. A comprehensive search was conducted to identify all case-control studies of maternal MTHFR and MTRR polymorphisms and NTD risk. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Overall, we found that maternal MTHFR C677T polymorphism (OR(TvsC) =1.20; 95% CI = 1.13-1.28) and MTRR A66G polymorphism (OR(GvsA) = 1.21; 95% CI = 0.98-1.49) were risk factors for producing offspring with NTD but maternal MTHFR A1298C polymorphism (OR(CvsA) = 0.91; 95% CI = 0.78-1.07) was not associated with NTD risk. However, in stratified analysis by geographical regions, we found that the maternal C677T polymorphism was significantly associated with the risk of NTD in Asian (OR(TvsC) = 1.43; 95% CI: 1.05-1.94), European (OR(TvsC) = 1.13; 95% CI: 1.04-1.24) and American (OR(TvsC) = 1.26; 95% CI: 1.13-1.41) populations. In conclusion, present meta-analysis supports that the maternal MTHFR C677T and MTRR A66G are polymorphisms contributory to risk for NTD.

Citing Articles

Dietary folic acid intake, 13 genetic variants and other factors with red blood cell folate concentration in pregnancy-preparing population.

He W, Zhang Y, Chen X, Dou Y, He Y, Yan W Eur J Nutr. 2024; 63(8):2921-2931.

PMID: 39153125 PMC: 11519176. DOI: 10.1007/s00394-024-03474-z.

Genome-wide analysis of spina bifida risk variants in a case-control study from Bangladesh.

Tindula G, Issac B, Mukherjee S, Ekramullah S, Arman D, Islam J Birth Defects Res. 2024; 116(3):e2331.

PMID: 38526198 PMC: 10963057. DOI: 10.1002/bdr2.2331.

ARMC5 controls the degradation of most Pol II subunits, and ARMC5 mutation increases neural tube defect risks in mice and humans.

Luo H, Lao L, Au K, Northrup H, He X, Forget D Genome Biol. 2024; 25(1):19.

PMID: 38225631 PMC: 10789052. DOI: 10.1186/s13059-023-03147-w.

Metabolic Analysis of Methylenetetrahydrofolate Reductase Single Nucleotide Polymorphisms (MTHFR 677C<T and MTHFR 1298A<C), Serum Folate and Vitamin B12 in Neural Tube Defects.

Hassan M, Raslan M, Tharwat M, Sakhr H, El-Khateeb E, Sakr S Indian J Clin Biochem. 2023; 38(3):305-315.

PMID: 37234187 PMC: 10205924. DOI: 10.1007/s12291-022-01049-5.

Association of Methylenetetrahydrofolate Reductase Gene Polymorphism in Mothers With Adverse Clinical Outcomes in Neonates.

Panigrahi D, Patel S, Rajbhar S, Padhi P, Shah S, Nanda R Cureus. 2023; 15(4):e38001.

PMID: 37223177 PMC: 10203823. DOI: 10.7759/cureus.38001.

References

Kirke P, Molloy A, Daly L, Burke H, Weir D, Scott J . Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med. 1993; 86(11):703-8. View

Guenther B, Sheppard C, Tran P, Rozen R, Matthews R, Ludwig M . The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol. 1999; 6(4):359-65. DOI: 10.1038/7594. View

Yang S, Zhang J, Feng C, Huang G . MTHFR 677T variant contributes to diabetic nephropathy risk in Caucasian individuals with type 2 diabetes: a meta-analysis. Metabolism. 2012; 62(4):586-94. DOI: 10.1016/j.metabol.2012.10.004. View

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Candito M, Rivet R, Herbeth B, Boisson C, Rudigoz R, Luton D . Nutritional and genetic determinants of vitamin B and homocysteine metabolisms in neural tube defects: a multicenter case-control study. Am J Med Genet A. 2008; 146A(9):1128-33. DOI: 10.1002/ajmg.a.32199. View

Naushad S, Devi A . Role of parental folate pathway single nucleotide polymorphisms in altering the susceptibility to neural tube defects in South India. J Perinat Med. 2010; 38(1):63-9. DOI: 10.1515/jpm.2009.119. View

Pogribny I, James S, Jernigan S, Pogribna M . Genomic hypomethylation is specific for preneoplastic liver in folate/methyl deficient rats and does not occur in non-target tissues. Mutat Res. 2004; 548(1-2):53-9. DOI: 10.1016/j.mrfmmm.2003.12.014. View

Relton C, Wilding C, Laffling A, Jonas P, Burgess T, Binks K . Low erythrocyte folate status and polymorphic variation in folate-related genes are associated with risk of neural tube defect pregnancy. Mol Genet Metab. 2004; 81(4):273-81. DOI: 10.1016/j.ymgme.2003.12.010. View

10.

Lee B, Cheong H, Shin Y, Cho B, Wang K . The effect of C677T mutation of methylene tetrahydrofolate reductase gene and plasma folate level on hyperhomocysteinemia in patients with meningomyelocele. Childs Nerv Syst. 2000; 16(9):559-63. DOI: 10.1007/PL00007298. View

11.

Parle-McDermott A, Mills J, Kirke P, OLeary V, Swanson D, Pangilinan F . Analysis of the MTHFR 1298A-->C and 677C-->T polymorphisms as risk factors for neural tube defects. J Hum Genet. 2003; 48(4):190-3. DOI: 10.1007/s10038-003-0008-4. View

12.

Zhu H, Wicker N, Shaw G, Lammer E, Hendricks K, Suarez L . Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab. 2003; 78(3):216-21. DOI: 10.1016/s1096-7192(03)00008-8. View

13.

Volcik K, Blanton S, Tyerman G, Jong S, Rott E, Page T . Methylenetetrahydrofolate reductase and spina bifida: evaluation of level of defect and maternal genotypic risk in Hispanics. Am J Med Genet. 2000; 95(1):21-7. View

14.

Yu J, Chen B, Zhang G, Fu S, Li P . The 677 C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in five Chinese ethnic groups. Hum Hered. 2000; 50(4):268-70. DOI: 10.1159/000022929. View

15.

van der Put N, van den Heuvel L, Steegers-Theunissen R, Trijbels F, Eskes T, Mariman E . Decreased methylene tetrahydrofolate reductase activity due to the 677C-->T mutation in families with spina bifida offspring. J Mol Med (Berl). 1996; 74(11):691-4. DOI: 10.1007/s001090050073. View

16.

James S, Pogribny I, Pogribna M, Miller B, Jernigan S, Melnyk S . Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr. 2003; 133(11 Suppl 1):3740S-3747S. DOI: 10.1093/jn/133.11.3740S. View

17.

Speer M, Worley G, Mackey J, Melvin E, Oakes W, George T . The thermolabile variant of methylenetetrahydrofolate reductase (MTHFR) is not a major risk factor for neural tube defect in American Caucasians. The NTD Collaborative Group. Neurogenetics. 2000; 1(2):149-50. DOI: 10.1007/s100480050022. View

18.

Olteanu H, Munson T, Banerjee R . Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002; 41(45):13378-85. DOI: 10.1021/bi020536s. View

19.

van der Linden I, den Heijer M, Afman L, Gellekink H, Vermeulen S, Kluijtmans L . The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. J Mol Med (Berl). 2006; 84(12):1047-54. DOI: 10.1007/s00109-006-0093-x. View

20.

Pejchal R, Campbell E, Guenther B, Lennon B, Matthews R, Ludwig M . Structural perturbations in the Ala --> Val polymorphism of methylenetetrahydrofolate reductase: how binding of folates may protect against inactivation. Biochemistry. 2006; 45(15):4808-18. PMC: 1868400. DOI: 10.1021/bi052294c. View